Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1.

Autor: Abend JR; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA. Electronic address: joabend@gmail.com., Sathe A; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA., Wrobel MB; Novartis Institutes for BioMedical Research, Biologics, Basel, Switzerland., Knapp M; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA., Xu L; Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, New Jersey, USA., Zhao L; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA., Kim P; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA., Desai S; Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, New Jersey, USA., Nguyen A; Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, New Jersey, USA., Leber XC; Novartis Institutes for BioMedical Research, Biologics, Basel, Switzerland., Hein A; Novartis Institutes for BioMedical Research, Biologics, Basel, Switzerland., Scharenberg M; Novartis Institutes for BioMedical Research, Biologics, Basel, Switzerland., Shaul J; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA., Ornelas E; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA., Wong K; Novartis Institutes for BioMedical Research, Infectious Disease Area, Emeryville, California, USA., Pietzonka T; Novartis Institutes for BioMedical Research, Biologics, Basel, Switzerland., Sterling LM; Celerion, Lincoln, Nebraska, USA., Hodges MR; Amplyx Pharmaceuticals, San Diego, California, USA., Pertel P; Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, New Jersey, USA., Traggiai E; Novartis Institutes for BioMedical Research, Biologics, Basel, Switzerland., Patick AK; Amplyx Pharmaceuticals, San Diego, California, USA., Kovacs SJ; Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, New Jersey, USA.

Publikováno v: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2024 Nov; Vol. 24 (11), pp. 1994-2006. Date of Electronic Publication: 2024 Jul 10.

Disease Association of Anti‒Carboxyethyl Lysine Autoantibodies in Hidradenitis Suppurativa.

Autor: Macchiarella G; Biomarker Development (BMD), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; Biozentrum, Faculty of Sciences, University of Basel, Basel, Switzerland., Cornacchione V; NIBR Biologics Center (NBC), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Cojean C; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Riker J; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Wang Y; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Te H; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Ceci M; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Gudjonsson JE; Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA., Gaulis S; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Goetschy JF; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Wollschlegel A; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Gass SK; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Oetliker-Contin S; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Wettstein-Ling B; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Schaefer DJ; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland., Meschberger P; Department of Surgery, Kantonsspital Baselland, Liestal, Switzerland., de Roche R; Praxis beim Merian Iselin, Basel, Switzerland., Osinga R; Department of Plastic, Reconstructive & Aesthetic Surgery and Hand Surgery, University Hospital, University of Basel, Switzerland; Praxis beim Merian Iselin, Basel, Switzerland., Wieczorek G; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Naumann U; Chemical Biology and Therapeutics (CBT), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Lehmann JCU; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Schubart A; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Hofmann A; Biotherapeutic and Analytical Technologies, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Roth L; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Florencia EF; Department of Dermatology, Erasmus University Medical Centre, Rotterdam, the Netherlands., Loesche C; Translational Medicine, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Traggiai E; NIBR Biologics Center (NBC), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Avrameas A; Biomarker Development (BMD), Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Prens EP; Department of Dermatology, Erasmus University Medical Centre, Rotterdam, the Netherlands., Röhn TA; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Roediger B; Autoimmunity, Transplantation and Inflammation (ATI) Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Electronic address: ben.roediger@novartis.com.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2023 Feb; Vol. 143 (2), pp. 273-283.e12. Date of Electronic Publication: 2022 Sep 16.

Characterization of B cells in synovial fluid and tissue from patients with JIA

Autor: Ferlito F, Corcione A, Traggiai E, Gregorio A, Martini A, Pistoia V, Gattorno M

Publikováno v: Pediatric Rheumatology Online Journal, Vol 6, Iss Suppl 1, p P21 (2008)

Externí odkaz: https://doaj.org/article/de3a6099b0dd4bb8add1e57637e20665

Critical role of WASp in germinal center tolerance through regulation of B cell apoptosis and diversification.

Autor: Descatoire M; Laboratory of Inherited Immune Disorders, Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Electronic address: marc.descatoire@chuv.ch., Fritzen R; University of St Andrews, St Andrews, UK., Rotman S; Service of Clinical Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Kuntzelman G; Novartis Institutes for BioMedical Research, Basel, Switzerland., Leber XC; Novartis Institutes for BioMedical Research, Basel, Switzerland., Droz-Georget S; Laboratory of Inherited Immune Disorders, Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Thrasher AJ; University College of London, Great Ormond Street Institute of Child Health, London, UK., Traggiai E; Novartis Institutes for BioMedical Research, Basel, Switzerland., Candotti F; Laboratory of Inherited Immune Disorders, Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Publikováno v: Cell reports [Cell Rep] 2022 Mar 08; Vol. 38 (10), pp. 110474.

Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD).

Autor: Papa R; Center for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy; DINOGMI, Università di Genova, Genoa, Italy., Rusmini M; Laboratory of Genetics and Genomics of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Schena F; Center for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Traggiai E; Novartis Institutes for Biomedical Research, Basel, Switzerland., Coccia MC; Unit of Pathology, Department of Translational Research, Laboratory Medicine, Diagnostics and Services, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Caorsi R; Center for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Arrigo S; Pediatric Gastroenterology and Endoscopy Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Pasetti F; Interventional Radiology and Neuroradiology Unit, Istituto G Gaslini, Genoa, Italy., Signa S; Center for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Barone P; Department of Pediatrics, University of Catania, Catania, Italy., Santamaria G; Laboratory of Genetics and Genomics of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Spirito G; Area of Neurobiology, SISSA, Trieste, Italy., Sanges R; Area of Neurobiology, SISSA, Trieste, Italy., Vozzi D; RNA Central Lab, IIT, Genova, Italy., Cavalli A; RNA Central Lab, IIT, Genova, Italy., Gustincich S; RNA Central Lab, IIT, Genova, Italy., Ravelli A; DINOGMI, Università di Genova, Genoa, Italy; Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Gattorno M; Center for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Ceccherini I; Laboratory of Genetics and Genomics of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Volpi S; Center for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy; DINOGMI, Università di Genova, Genoa, Italy. Electronic address: stefanovolpi@gaslini.org.

Publikováno v: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2021 Oct; Vol. 231, pp. 108837. Date of Electronic Publication: 2021 Aug 26.